Literature DB >> 25542838

Impact of Comorbidities on Prostate Cancer Stage at Diagnosis in Florida.

Hong Xiao1, Fei Tan2, Pierre Goovaerts3, Georges Adunlin4, Askal Ayalew Ali4, Clement K Gwede5, Youjie Huang6.   

Abstract

To examine the association of major types of comorbidity with late-stage prostate cancer, a random sample of 11,083 men diagnosed with prostate cancer during 2002-2007 was taken from the Florida Cancer Data System. Individual-level covariates included demographics, primary insurance payer, and comorbidity following the Elixhauser Index. Socioeconomic variables were extracted from Census 2000 data and merged to the individual level data. Provider-to-case ratio at county level was alsocomputed. Multilevel logistic regression was used to assess associations between these factors and late-stage diagnosis of prostate cancer. Higher odds of late-stage diagnosis was significantly related to presence of comorbidities, being unmarried, current smoker, uninsured, and diagnosed in not-for-profit hospitals. The study reported that the presence of certain comorbidities, specifically 10 out of the 45, was associated with late-stage prostate cancer diagnosis. Eight out of 10 significant comorbid conditions were associated with greater risk of being diagnosed at late-stage prostate cancer. On the other hand, men who had chronic pulmonary disease, and solid tumor without metastasis, were less likely to be diagnosed with late-stage prostate cancer. Late-stage diagnosis was associated with comorbidity, which is often associated with increased health care utilization. The association of comorbidity with late-stage prostate cancer diagnosis suggests that individuals with significant comorbidity should be offered routine screening for prostate cancer rather than focusing only on managing symptomatic health problems.
© The Author(s) 2014.

Entities:  

Keywords:  comorbidity; health care utilization; health inequality/disparity; health screening; prostate cancer

Mesh:

Year:  2014        PMID: 25542838      PMCID: PMC4483149          DOI: 10.1177/1557988314564593

Source DB:  PubMed          Journal:  Am J Mens Health        ISSN: 1557-9883


  46 in total

Review 1.  Racial and ethnic disparities in the receipt of cancer treatment.

Authors:  Vickie L Shavers; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2002-03-06       Impact factor: 13.506

2.  Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.

Authors:  Vickie L Shavers; Martin L Brown; Arnold L Potosky; Carrie N Klabunde; W W Davis; Judd W Moul; Angela Fahey
Journal:  J Gen Intern Med       Date:  2004-02       Impact factor: 5.128

3.  Effects of health insurance and race on early detection of cancer.

Authors:  R G Roetzheim; N Pal; C Tennant; L Voti; J Z Ayanian; A Schwabe; J P Krischer
Journal:  J Natl Cancer Inst       Date:  1999-08-18       Impact factor: 13.506

4.  Racial and geographic disparities in late-stage prostate cancer diagnosis in Florida.

Authors:  Hong Xiao; Fei Tan; Pierre Goovaerts
Journal:  J Health Care Poor Underserved       Date:  2011

5.  Association between ethnicity and prostate cancer outcomes across hospital and surgeon volume groups.

Authors:  Ravishankar Jayadevappa; Sumedha Chhatre; Jerry C Johnson; Stanley Bruce Malkowicz
Journal:  Health Policy       Date:  2010-08-13       Impact factor: 2.980

6.  Benefits, barriers, sources of influence, and prostate cancer screening among rural men.

Authors:  JoAnn S Oliver; Cecelia G Grindel; Jamie DeCoster; Cassandra D Ford; Michelle Y Martin
Journal:  Public Health Nurs       Date:  2011-05-25       Impact factor: 1.462

7.  Explaining the race difference in prostate cancer stage at diagnosis.

Authors:  Beth A Jones; Wen-Liang Liu; Andre B Araujo; Stanislav V Kasl; Stephanie N Silvera; Hosanna Soler-Vilá; Mary G M Curnen; Robert Dubrow
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09-30       Impact factor: 4.254

8.  The role of area-level influences on prostate cancer grade and stage at diagnosis.

Authors:  Ann C Klassen; Frank C Curriero; Jean Hee Hong; Chyvette Williams; Martin Kulldorff; Helen I Meissner; Anthony Alberg; Margaret Ensminger
Journal:  Prev Med       Date:  2004-09       Impact factor: 4.018

Review 9.  The epidemiology of prostate cancer part II: the risk factors.

Authors:  O W Brawley; K Knopf; I Thompson
Journal:  Semin Urol Oncol       Date:  1998-11

10.  Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations.

Authors:  C Bartsch; H Bartsch; A Schmidt; S Ilg; K H Bichler; S H Flüchter
Journal:  Clin Chim Acta       Date:  1992-08-31       Impact factor: 3.786

View more
  4 in total

1.  Risk factors for metastatic prostate cancer: A sentinel event case series.

Authors:  Channing J Paller; Alexander P Cole; Alan W Partin; Michael A Carducci; Norma F Kanarek
Journal:  Prostate       Date:  2017-08-08       Impact factor: 4.104

2.  Association between Types of Chronic Conditions and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Prostate Cancer.

Authors:  Amit D Raval; Suresh Madhavan; Malcolm D Mattes; Usha Sambamoorthi
Journal:  Popul Health Manag       Date:  2016-03-31       Impact factor: 2.459

Review 3.  Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms.

Authors:  Cristina Renzi; Aradhna Kaushal; Jon Emery; Willie Hamilton; Richard D Neal; Bernard Rachet; Greg Rubin; Hardeep Singh; Fiona M Walter; Niek J de Wit; Georgios Lyratzopoulos
Journal:  Nat Rev Clin Oncol       Date:  2019-07-26       Impact factor: 66.675

4.  Pain, fatigue and depression symptom cluster in survivors of prostate cancer.

Authors:  Manisha Baden; Liya Lu; Frances J Drummond; Anna Gavin; Linda Sharp
Journal:  Support Care Cancer       Date:  2020-01-24       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.